Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04035447
Other study ID # Pro00103249
Secondary ID 1K08CA245107-01
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 22, 2020
Est. completion date May 30, 2024

Study information

Verified date February 2024
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Symptom interference is common for survivors of young adult cancer (aged 18-39 at diagnosis) and impacts their abilities to achieve normative life goals (e.g., education, careers, independence, romantic/social relationships) as well as adhere to recommended follow-up care. Assistance with symptom management has been rated by young adult survivors as an important and unmet healthcare need; however, skill-based symptom management interventions have typically been tested among older cancer survivors and have not targeted the unique developmental needs of those diagnosed as young adults. The proposed research advances the health and wellbeing of young adult cancer survivors by creating a developmentally appropriate hybrid in-person/mHealth behavioral symptom management intervention which addresses variables (i.e., symptoms and symptom interference) consistently linked to significant social, economic, and health burden.


Description:

More than 60,000 young adults (YAs) aged 18-39 are diagnosed with cancer in the US each year. Advances in treatment have yielded five year survival rates >70% suggesting that the majority of YAs will become long-term cancer survivors. Symptom (e.g., pain, fatigue, distress) interference is common for YA cancer survivors and impacts their abilities to achieve normative life goals (e.g., returning to work/school, achieving autonomy, pursuing social/romantic relationships) and adhere to recommended follow-up care. Symptom management has been identified as a significant issue in the transition to survivorship for YAs by the Institute of Medicine and National Cancer Institute, and assistance with symptom management is rated as an important and unmet need by YA survivors. Yet, behavioral symptom management interventions have not targeted the needs of those diagnosed as YAs. The proposed study aims to develop and test the feasibility and acceptability of a novel behavioral symptom management intervention designed for survivors of YA cancer (cancer types: hematologic, breast, or gastrointestinal cancers, melanoma, or germ cell tumors). The hybrid intervention will include inperson, group sessions and an integrated mobile application. The intervention will provide peer support while also teaching skills to improve symptoms, symptom interference, and self-efficacy for symptom management. The mobile application will assist with symptom monitoring, home skills practice, and connecting with group members. The preliminary version of the intervention will be guided by the research team's prior work developing and testing symptom management interventions for cancer survivors, national guidelines for YA oncology, consultation with an expert advisory board, and input from patient (n=20) and provider N=10) stakeholders. The intervention will be further refined following review by patient user testers (n=10). Next, feasibility, acceptability, and distributions of change over time as well as relationships between outcome variables will be examined through a pilot randomized clinical trial of the developed intervention. Participants (N=60) will be randomized to intervention or wait-list control arms. Primary study outcomes are symptom (pain, fatigue, distress) severity and symptom interference. Self-efficacy and support will also be examined as mediators of change in outcome variables. The proposed study has the potential to make several significant contributions by targeting an underserved group of cancer survivors, addressing a critical gap in care, and addressing variables consistently linked to social, economic, and health burden for YAs. It will also provide important information about approaches to identify, recruit, and retain YA cancer survivors in research and provide pilot data for a larger trial.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 120
Est. completion date May 30, 2024
Est. primary completion date May 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 39 Years
Eligibility Young Adult Cancer Survivors Participating in Intervention Development Interviews Eligibility Criteria - Diagnosed with hematologic, breast, gastrointestinal, or endocrine cancers, melanoma, or germ cell tumors - Diagnosed with cancer as a young adult - Under the care of a medical provider at the Duke Cancer Institute - Completed curative treatment involving multimodal therapy within the last five years - Able to speak and read English - Able to give informed consent Exclusion Criteria - Nonambulatory - Major mental illness, i.e., schizophrenia - Untreated or uncontrolled mental illness, i.e., bipolar - Residence greater than 100 miles from the research site Medical Providers Participating in Intervention Development Interviews Eligibility criteria o Provide care to young adult cancer survivors at the Duke Cancer Institute Young Adult Cancer Survivor User Testers Eligibility Criteria - Diagnosed with hematologic, breast, gastrointestinal cancers, or endocrine cancers, melanoma, or germ cell tumors - Diagnosed with cancer as a young adult - Under the care of a medical provider at the Duke Cancer Institute - Completed curative treatment involving multimodal therapy within the last five years - Able to speak and read English - Able to give informed consent Exclusion Criteria - Nonambulatory - Major mental illness, i.e., schizophrenia - Untreated or uncontrolled mental illness, i.e., bipolar - Residence great than 100 miles from the research site RCT Participants Eligibility Criteria: - diagnosed with cancer as a YA (aged 18-39) - diagnosis of hematologic, breast, endocrine or gastrointestinal cancer, melanoma, or germ cell tumor - receiving care at the Duke Cancer Institute - completed curative treatment involving multimodal therapy within the last 2 years - able to speak/read English; and able to give informed consent. Exclusion Criteria: - non-ambulatory - major mental illness (i.e., schizophrenia) - untreated or uncontrolled mental illness (i.e., bipolar disorder)

Study Design


Intervention

Behavioral:
Behavioral Symptom Management for Young Adult Cancer Survivors
The intervention includes group sessions held over Zoom along with an integrated mobile application to provide participants with instruction in cognitive and behavioral strategies for managing symptoms (i.e., pain, fatigue, distress). The developed intervention includes 8 face-to-face group sessions (12 therapy hours). Sessions are delivered using a faded contact approach (i.e., sessions 1-6: weekly, sessions 7-8: biweekly). Participants receive secure access to a study-specific mobile application that includes: 1) audio and video files and brief text-based educational content reviewing strategies discussed during the groups; 2) the ability to self-monitor symptom severity; 3) the ability to connect with group members via a social networking platform; and 4) activity tracking synchronization.

Locations

Country Name City State
United States Duke Cancer Institute Durham North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Duke University National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Sociodemographics Age, race/ethnicity, relationship status, employment status, occupation, income, and years fo education Baseline
Other Disease Characteristics Disagnosis and treatment information Baseline
Other Change in Activity: International Physical Activity Questionnaire The International Physical Activity Questionnaire is a seven-item questionnaire that assesses the amount of time participants have spent doing physical activity (e.g., moderate physical activities, vigorous physical activities, walking) in the last seven Baseline and again 3, 6, 9, and 12 months following the baseline assessment
Other Change in Activity: Stanford LCAT The Stanford LCAT is a categorical item that asseses the type of physical activities participants do. Baseline and again 3, 6, 9, and 12 months following the baseline assessment
Other Change in Spritual Well-Being: Functional Assessment of Chronic Illness Therapy (FACIT) The FACIT assesses the spiritual wellbeing of participants with 12-item questionnaire on a scale from 0 = "not at all" to 4 = "very much." Baseline and again 3, 6, 9, and 12 months following the baseline assessment
Other Changes in Cancer Experience: Acceptance and Action Questionnaires for Cancer (AAQ) The AAQ is a 7-item questionnaire to track psychological flexibility related to coping with cancer and cancer treatment. The scale ranges from 1 = "never true" to 7 "always true." Item is scored by adding all of the responses together. Baseline and again 3, 6, 9, and 12 months following the baseline assessment
Other Changes in Living in Alignment with Values: The Valuing Questionnaire (VQ) The VQ is a 10-item self-report questionnaire with a scale 0 = "not true at all" to 6 "completely true." Baseline and again 3, 6, 9, and 12 months following the baseline assessment
Primary Intervention Satistfaction: SSTS-R Intervention satisfaction will be assessed using the SSTS-R, a 13-item measure with the first 12-items on a five-point scale ranging from 1 "strongly disagree" to 5 "strongly disagree." The 13th item asks, "How much did the intervention help with your sypmtoms?" with 5 answer choices ranging from "made things a lot better" to made things a lot worse." Following completion of the intervention, up to 12 months
Primary Open-Ended Questions About the Program Intervention will be evaluated using 3 open-ended questions, including the following: "1) What was the most helpful part of the program?," "2) What was the least helpful part of the program?", and "3) What suggestions do you have for us to help improve the program?" Following completion of the intervention, up to 12 months
Primary Session attendance Treatment feasibility will be assessed by measuring the session attendance rate for each participant. Following completion of the intervention, up to 12 months
Primary Treatment Acceptability Questionnaire The Treatment Acceptability Questionnaire is a six-item scale assessing participants' views of an intervention as acceptable, ethical, and effective.
Items are rated on a 7-point Likert scale (e.g., 1 "very unacceptable" to 7 "very acceptable).
Following completion of the intervention, up to 12 months
Primary Change in Depressive Symptoms: PROMIS Depression Short Form Depressive Symptoms will be assessed using the PROMIS Depression Short Form, an 8-item measure assessing symptoms of depression in the last week. Participants are asked to respond to items (e.g., "I felt sad," "I felt helpless") using a five-point scale ranging from 1 "never" to 5 "always." Baseline and again 3, 6, 9, and 12 months following the baseline assessment
Primary Change in Anxiety: PROMIS Anxiety Short Form Symptoms of Anxiety will be assessed using the PROMIS Anxiety Short Form, an 8-item measure assessing symptoms of anxiety in the last week. Participants are asked to respond to items (e.g., "I felt nervous," "I felt tense") using a five-point scale ranging from 1 "never" to 5 "always". Baseline and again 3, 6, 9, and 12 months following the baseline assessment
Primary Change in Symptom Interference: Illness intrusiveness rating scale Symptom interference will be assessed using the Illness Intrusiveness Rating Scale (IIRS). The IIRS assesses the extent to which an illness and/ or its treatments interfere with 13 quality of life domains (e.g., health, diet, work, sex life, active recreation). Items are rated on a 7-point scale from 1 "not very much" to 7 "very much." Baseline and again 3, 6, 9, and 12 months following the baseline assessment
Primary Use of Intervention Strategies Participants' use of intervention strategies will be assessed using a measure developed specific to components of the proposed intervention. Participants will be asked about how frequently treatment strategies discussed in session have been used outside of session since the previous session or last assessment depending on the timing of the questionnaire. A scale ranging from 0 "not at all" to 5 "2 or more times a day" will be used. Following completion of the intervention, up to 12 months
Primary Self-reported use of the Mobile Application Participants' use of the mobile application will be assessed using a measure developed specific to components of the proposed mobile application.
Participants will be asked about how frequently they have used components of the mobile application outside of session since the previous session or last assessment depending on the timing of the questionnaire. A scale ranging from 0 "not at all" to 5 "2 or more times a day" will be used.
Following completion of the intervention, up to 12 months
Primary Change in Pain: Brief Pain Inventory The Brief Pain Inventory is a 9-item, self-report measure assessing pain severity and interference from pain across important life domains (e.g., general activity, work, relations with others). Participants rate their pain on a scale from 0 "no pain" to 10 "pain as bad as you can imagine." Baseline and again 3, 6, 9, and 12 months following the baseline assessment
Primary Change in Fatigue: PROMIS Fatigue Short Form Fatigue will be assessed using the PROMIS Fatigue Scale, a 6-item self-report measure of fatigue. Participants are asked to think about the last week when responding to each item (e.g., "In the past 7 days, how run-down did you feel, on average?"). Respon Baseline and again 3, 6, 9, and 12 months following the baseline assessment
Secondary Group Therapy Experiences Scale The 17-item Group Therapy Experiences Scale will be used to assess the level of cohesion among group members (e.g., development of positive relationships, comfort level with other group members). Items 1-16 are rated on a 5-point scale with 1 = "strongly agree" to 5 = "strongly disagree." Item 17 is an open-ended question, "was there something in the group today that helped or hindered you?"relationships, comfort level with other group members). Items are rated on a 4-point scale with 1= "strongly disagree" to 4= "strongly agree." Following completion of the intervention, up to 12 months
Secondary Change in Social Isolation: PROMIS Social Isolation Scale The PROMIS Social Isolation Scale is a 6-item measure is used to assess social isolation. Participants are asked to rate each item (e.g., "I felt left out," "I feel that people avoid talking to me") on a scale from 1= "never" to 5= "always." Baseline and again 3, 6, 9, and 12 months following the baseline assessment
Secondary Change in Self-Efficacy: The Self-Efficacy for Managing Chronic Disease Scale The Self-Efficacy for Managing Chronic Disease Scale is a 6-item scale. Participants rate their confidence in keeping pain, fatigue, emotional distress, and other symptoms from interfering with things they want to do on a scale from 1 "not at all confident" to 10 "totally confident." Baseline and again 3, 6, 9, and 12 months following the baseline assessment
Secondary Change in Self-Efficacy: PROMIS Self-Efficacy for Managing Chronic Conditions - Managing Symptoms - Short Form 4a The PROMIS Self-Efficacy for Managing Chronic Conditions - Managing Symptoms - Short Form 4a is a 4-item scale. Participants rate their confidence in managing their symptoms during daily activities, with relationships with friends and family, in a public place, and working with their doctor to manage these symptoms on a scale from 1 = "I am not at all confident" to 5 "I am very confident." Baseline and again 3, 6, 9, and 12 months following the baseline assessment
Secondary Change in Emotional Support: PROMIS Emotional Support-Short Form The PROMIS Emotional Support Short Form is a 6-item measure used to assess emotional support. Participants are asked to rate each item ("I have someone who will listen to me when I need to talk," "I have someone to talk with when I have a bad day") on a scale from 1= "never" to 5= "always." Baseline and again 3, 6, 9, and 12 months following the baseline assessment
Secondary Change in Instrumental Support: PROMIS Instrumental Support-Short Form The PROMIS Instrumental Support Short Form is a 6-item measure used to assess instrumental support. Participants are asked to rate each item (e.g., "Do you have someone to take you to the doctor if you needed it?," "Do you have someone to prepare your meals if you are unable to do it yourself?") on a scale from 1= "never" to 5= "always." Baseline and again 3, 6, 9, and 12 months following the baseline assessment
Secondary Change in Informational Support: PROMIS Informational Support-Short Form The PROMIS Informational Support Short Form is a 6-item measure used to assess informational support. Participants are asked to rate each item (e.g., "I have someone to turn to for suggestions about how to deal with a problem," "I have someone to give me information if I need it") on a scale from 1= "never" to 5= "always." Baseline and again 3, 6, 9, and 12 months following the baseline assessment
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2